Market Overview
The worldwide demand for Erythropoietin Drugs Market Share also referred as hematopoietic drugs is expected to remain strong in the forthcoming years. Market Research Future (MRFR) reports that the global erythropoietin drug market will post a above-average CAGR between 2017 and 2023. The outlook remains positive for the global erythropoietin drug market for the medium terms.
Erythropoietin drug are used for treating a wide range of disorders, which include AIDS, chronic renal diseases, anaemia, cancer, among others. Increased prevalence of such diseases is boosting the sales of erythropoietin. Over the years, tremendous investment has been made in research & development programs focused on drug discovery, which has also influenced the market growth to certain extent. Several new erythropoietin drug combinations have come up in recent years. Introduction of new drug combinations is allowing to drug makers to cater to wider pool of patients.
Rising awareness among patients and increased focus on improving healthcare services in the developing countries is likely to open new growth avenues for market players in near future. On the other hand, most of the erythropoietin drug available are highly priced, which makes their penetration in price sensitive markets difficult. This is viewed as a major market constraint. Patient expiry and introduction of generic variants may provide an impetus to drug penetration. Focus is also shifting on developing alternative drugs formulations.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1360
Segmental Overview
MRFR’s report includes a thorough segmental analysis of the global erythropoietin drug market based on product type, application and end user.
On the basis of product type, the market has been segmented into second generation formulation, first generation formulation and biosimilars. On the basis of application, the market has been segmented into renal diseases, HIV, oncology and other. On the basis of end user, the market has been segmented into pharmacy and hospital.
Global Erythropoietin Drug Market: Regional Segmentation
On the basis of region, the market has been segmented into North America, South America, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA). North America represents the largest market for Erythropoietin. This growth can be partly attributed to rising cancer prevalence and increased incidence of renal diseases in the U.S. and Canada. Other factors that favour the market growth in the region include widespread accessibility of cutting-edge medical services and strong government support. North America is followed by Europe and APAC respectively. The market is likely to witness towering gains in APAC in particular. In addition, the APAC erythropoietin drug market is projected to exhibit the fastest growth during the forecast period. Increased penetration of healthcare services and expanding patient population in countries such as China and India. Moreover, increased government effort to improve healthcare in these countries is creating further opportunities. LatAm and the MEA regions hold relatively lower share of the global erythropoietin drug market.
Competitive Landscape
Amgen (US), Teva Pharmaceutical Industries Ltd. (Israel), Emcure Pharmaceuticals (India), Hospira (US), LG Life Sciences Ltd. (Korea), Kyowa Hakko Kirin, Boehringer Ingelheim (US), Intas Pharmaceuticals (India), Hoffmann-La Roche (Switzerland), Johnson & Johnson (US), Celltrion, Inc. (South Korea), 3SBio, Biocon (India), BIOSIDUS (Argentina), and Dahua Pharmaceutical (China).
Browse Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/erythropoietin-drug-market-1360
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]
Erythropoietin, also known as hemotopoietin, is a hormone produced by the kidneys for the continuous production of red blood cells.
The global erythropoietin drug market report by Market Research Future (MRFR) has been compiled after undertaking painstaking primary and secondary research.
According to the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK), close to 661,000 people were diagnosed with chronic kidney disease.
This can fuel the demand for EPO drugs in the market.The large cases of ESRD has caused a surge of anemia among patients and portended to fuel the demand for erythropoietin drugs.
Approval of Epogen and commercialization of the drug as early as 2016 has facilitated market growth.
Low cost of therapeutics in developing economies of APAC and MEA will facilitate segment growth.By application, it is segmented into HIV, oncology, renal diseases, and others.On the basis of end user, it is divided into hospital and pharmacy.
It is a glycoprotein hormone that controls erythropoiesis or production of RBC.
Moreover, introduction of new drugs and different government initiatives for research fuels the market growth during the forecast period.Global erythropoietin drug market is growing with the rapid pace.
According to a recent study report published by the Market Research Future, global erythropoietin drug market is booming and expected to gain prominence over the forecast period.
The market is projected to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).Global erythropoietin drug market is expected to grow at a CAGR of 9.5% during forecasted period.Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1360Erythropoietin Drug Market Key PlayersThe global erythropoietin drug market is observed to be growing rapidly owing to increasing developments of key players like Hoffmann-La Roche (Switzerland), Johnson & Johnson (US), Amgen (US), Kyowa Hakko Kirin, Intas Pharmaceuticals (India), Teva Pharmaceutical Industries Ltd. (Israel), Biocon (India), Emcure Pharmaceuticals (India), Celltrion, Inc. (South Korea), Hospira (US), Dahua Pharmaceutical (China), LG Life Sciences Ltd. (Korea), 3SBio, Boehringer Ingelheim (US), BIOSIDUS (Argentina).Erythropoietin Drug Market SegmentationGlobal erythropoietin drug market is segmented on the basis of type of product into biosimilars, first generation formulation and second generation formulation.
On the basis of application market is segmented as oncology, renal diseases, HIV and other and on the basis of end user they are segmented into hospital and pharmacy.Erythropoietin Drug Market Regional AnalysisNorth America has the largest market share in global erythropoietin drug market owing to the increasing population of people suffering from cancer and renal diseases.
Erythropoietin drug market in Europe is growing owing to the development of numerous biosimilars which in turn increases the frequency of their usage.
